张朋｜复旦大学｜学者主页

期刊论文

2026

动脉自旋标记技术在新生儿获得性脑损伤中的应用进展:从血流动力学机制到精准医学

刘鹏，张朋，杨凤，王颖

《实用放射学杂志》

2024

Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression

L. Bai, Weiyi Qu, Xu Cheng, Hailong Yang, Yong-Ping Huang, Zhen-Ya Wang, Cui-Juan Han, Rui-Feng Tian, Fengjiao Hu, Ling Yang, Song Tian, Han Tian, Zhi-Wei Cai, Juan Wan, Jing-Wei Jiang, Jiajun Fu, Jun-Jie Zhou, Yu-Feng Hu, Tengfei Ma, Xin Zhang, Yan-Xiao Ji, Jing-Jing Cai, Zhi-Gang She, Yi-Bin Wang, Peng Zhang, Ling-Li Huang, Hongliang Li, Xiao-Jing Zhang

Science Translational Medicine

精选作品

期刊论文

动脉自旋标记技术在新生儿获得性脑损伤中的应用进展:从血流动力学机制到精准医学

Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy

Targeting peroxisome proliferator‐activated receptor γ proteasomal degradation by magnolol is a potential avenue for adipogenesis‐mediated metabolic homeostasis

Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.

High Remnant Cholesterol Level Potentiates the Development of Hypertension

Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities

TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease.

A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasis

A risk score based on baseline risk factors for predicting mortality in COVID-19 patients

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies

Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes

Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients

Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis

Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1

NAFLD as a continuous driver in the whole spectrum of vascular disease.

Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease.

A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis.

Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD

TNFAIP3 Interacting Protein 3 Is an Activator of Hippo‐YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury

The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin‐Mediated Degradation of 3‐Hydroxy‐3‐Methylglutaryl CoA Reductase Degradation Protein 1

Fatty Acid Synthase–Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD

A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques

The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19

Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species.

Heavy Disease Burden of High Systolic Blood Pressure During 1990-2019: Highlighting Regional, Sex, and Age Specific Strategies in Blood Pressure Control

Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta–Activated Kinase 1–c‐Jun‐N‐Terminal Kinase/p38 Signaling

Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation

Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China

Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes

NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Ca2+-Dependent NOX5 (NADPH Oxidase 5) Exaggerates Cardiac Hypertrophy Through Reactive Oxygen Species Production

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation.

Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality.

Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Epidemiological Features of NAFLD From 1999 to 2018 in China

Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19

Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3

Perioperative Presentation of COVID‐19 Disease in a Liver Transplant Recipient

STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy

Cardiolipin Synthase 1 Ameliorates NASH Through Activating Transcription Factor 3 Transcriptional Inactivation

Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice

Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator‐Activated Receptor γ in Mice

F‐box/WD Repeat‐Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal‐Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice

Reply:

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Carboxyl‐Terminal Modulator Protein Ameliorates Pathological Cardiac Hypertrophy by Suppressing the Protein Kinase B Signaling Pathway

Wang et al. reply

The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4

Reprogramming Innate Immune Signaling in Cardiometabolic Disease

An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia–reperfusion injury

Control of Pathological Cardiac Hypertrophy by Transcriptional Corepressor IRF2BP2 (Interferon Regulatory Factor-2 Binding Protein 2)

Targeting TMBIM 1 Alleviates Pathological Cardiac Hypertrophy

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

Interferon Regulatory Factor 4 Inhibits Neointima Formation by Engaging Krüppel-Like Factor 4 Signaling

Corrigendum: Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy

肝疾患:Tmbim1は多胞体調節因子であり,リソソームでのTlr4の分解を標的としてマウスやサルの非アルコール性脂肪性肝の発症を防止する

Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury.

A Long Non-Coding RNA Defines an Epigenetic Checkpoint in Cardiac Hypertrophy

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling

Abstract 026: Role of Tank in the Regulation of Pathological Cardiac Hypertrophy

Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling

Attenuation of cerebral ischemic injury in interferon regulatory factor 3‐deficient rat

Vinexin‐β deficiency protects against cerebral ischaemia/reperfusion injury by inhibiting neuronal apoptosis

Reply to: "Interferon regulatory factor 9 plays a dual function in health and disease".

Mindin regulates vascular smooth muscle cell phenotype and prevents neointima formation.

Oncostatin M Confers Neuroprotection against Ischemic Stroke

Exacerbating Pressure Overload-Induced Cardiac Hypertrophy: Novel Role of Adaptor Molecule Src Homology 2-B3.